SLC5A2 and type 2 diabetes mellitus: The SCORED study assessed the safety of sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, in 10,584 patients with T2D and impaired kidney function (eGFR 25–60 mL/min/1.73 m2) (14).